Therefore, we evaluated the serum myostatin level pre- and post-intervention and consider that awareness of specific changes in body composition during obesity weight loss treatment may guide optimal weight loss treatment strategies in preventing loss of skeletal muscle mass and decreasing body fat mass. This evidence concerns the gene MSTN and obesity disorder.